Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Moderator: 123414
Search This Board: 
Last Post: 10/10/2019 10:22:44 AM - Followers: 81 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF    



Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More : http://static.cdn-seekingalpha.com/instablog/19040961-e-vestorsgroup/2601761-theralase-technologies-inc-the-greatest-story-never-told

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Small Company Offering and Sale of Securities Without Registration (d) 09/10/2019 02:45:10 PM
TLTFF News: Small Company Offering and Sale of Securities Without Registration (d) 10/19/2018 04:24:41 PM
TLTFF News: Small Company Offering and Sale of Securities Without Registration (d) 05/29/2018 05:28:56 PM
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
#3660   The initial lab results were very impressive. 123414 10/10/19 10:22:44 AM
#3659   Theralase Technologi (TLTFF) mick 10/09/19 01:31:01 PM
#3658   https://theralase.com/events/theralase-technologies-corporate-presentation-toron -3 10/08/19 09:19:13 AM
#3657   The company has an investor presentation for 25 -3 10/07/19 09:26:16 PM
#3656   a little volume never hurt saigai 10/07/19 01:45:39 PM
#3655   The Company anticipates that patient enrollment and treatment 123414 10/07/19 07:47:27 AM
#3654   London Health Sciences Centre Launches as Newest Clinical 123414 10/07/19 07:41:55 AM
#3653   This article IMO contributed to Friday price decline. 123414 10/06/19 10:14:45 AM
#3652   READING, THANK YOU mick 10/05/19 04:03:26 PM
#3651   Small Company Offering and Sale of Securities Without mick 10/05/19 04:02:30 PM
#3650   Theralase Technologi (TLTFF) mick 10/05/19 04:02:07 PM
#3649   thank you for heads up; $TLTFF mick 10/05/19 04:01:55 PM
#3648   This manipulation is insane. Good news comes stainedone 10/02/19 12:13:55 PM
#3647   $TLTFF check out this link and see TLTFF $Pistol Pete$ 10/02/19 02:05:41 AM
#3646   News: $TLTFF Theralase Files Investigational New Drug Application whytestocks 10/01/19 09:40:25 AM
#3645   https://ceo.ca/@accesswire/theralase-files-investigational-new-drug-application -3 10/01/19 09:13:21 AM
#3644   Would suggest every one go for a walk -3 10/01/19 08:51:36 AM
#3643   TLTFF-Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment 123414 09/30/19 09:37:16 PM
#3642   This post will give you an idea why -3 09/30/19 07:02:33 PM
#3641   The stock has been in the short run -3 09/30/19 04:20:30 PM
#3640   With this amazing news, how is the stock J_Dean 09/30/19 04:08:02 PM
#3639   News: $TLTFF Patient Six Cancer-Free Eighteen Months After whytestocks 09/30/19 12:10:47 PM
#3638   i guess the news wasnt good enough. i saigai 09/30/19 09:46:49 AM
#3637   Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment 123414 09/30/19 08:09:46 AM
#3636   More sensible thoughts will prevail . -3 09/29/19 04:18:14 PM
#3635   That is said partially in jest . Price -3 09/28/19 03:06:20 PM
#3634   Some more DD . rog w. who -3 09/28/19 10:39:33 AM
#3633   Some DD on a stock with some complications -3 09/27/19 03:38:44 PM
#3632   No suerte88 09/27/19 10:12:58 AM
#3631   Geese, it just keeps going down! 52-week low, J_Dean 09/25/19 04:16:32 PM
#3630   I see i see, 10$ soon, not suerte88 09/25/19 03:01:30 PM
#3629   Good to have you back . -3 09/24/19 10:24:41 AM
#3628   Hi $Pistol Pete$ 123414 09/24/19 10:19:03 AM
#3627   Good morning $Pistol Pete$ 09/24/19 10:09:14 AM
#3626   18 MONTHS CANCER FREE FROM ONE TREATMENT. 123414 09/24/19 09:58:38 AM
#3625   Globe says Mackie rates Theralase "speculative buy" 123414 09/22/19 03:02:55 AM
#3624   TLTFF Speculative buy rating-Target price .60USD / .80CAD 123414 09/19/19 04:56:03 AM
#3623   That is the only news so far 1 -3 09/19/19 12:19:01 AM
#3622   Why only one patient started? You’d figure there’s J_Dean 09/18/19 05:57:14 PM
#3621   Science breakthrough discovery . If results in phase -3 09/18/19 04:50:11 PM
#3620   Andre Uddin is managing director, healthcare research at 123414 09/18/19 02:59:33 PM
#3619   Close to what? A potential buyout? J_Dean 09/18/19 07:55:05 AM
#3618   The insiders are lathered up with options we -3 09/18/19 07:18:48 AM
#3617   Getting ready for the pump . -3 09/13/19 08:44:35 PM
#3616   I can see clearly now. 123414 09/09/19 11:41:31 AM
#3615   The science is not something that is striking -3 09/05/19 07:58:06 AM
#3614   Market isn’t impressed with the recent PR? Smh J_Dean 09/04/19 11:26:31 AM
#3613   TLTFF-Treats first patient in Pivotal PH 2 Bladder_Cancer_study! 123414 09/04/19 07:53:14 AM
#3612   Theralase Annouces First Patient Treated in Phase II Gene_Simmons 09/04/19 07:37:39 AM
#3611   Operational Highlights: 123414 08/30/19 04:51:35 AM